BD1063
BD1063 is a selective sigma receptor antagonist, with a reported binding affinity of Ki = 9 ± 1 nM for the sigma-1 receptor, and 702 ± 147 nM for the sigma-2 receptor. It has been shown to reduce the effects of methamphetamine in animal studies.
Pharmacology[edit | edit source]
BD1063 is a drug which acts as an antagonist for sigma receptors. It is selective for the sigma-1 subtype, and has less affinity for the sigma-2 subtype. Sigma receptors are a set of proteins located in the brain, which are thought to be involved in various drug effects and diseases, including schizophrenia, depression, and drug addiction.
Effects[edit | edit source]
BD1063 has been shown to reduce the self-administration of methamphetamine in rats, suggesting that it may have potential for use in the treatment of methamphetamine addiction. It has also been shown to produce antidepressant-like effects in animal studies, suggesting potential applications in the treatment of depression.
See also[edit | edit source]
References[edit | edit source]
BD1063 Resources | ||
---|---|---|
|
|
|
Find a healthcare provider anywhere in the world quickly and easily!
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
WikiMD is the world's largest, free medical and wellness encyclopedia edited only by professionals. Advertise!
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD